



Not for distribution, directly or indirectly, in the United States of America, Australia, Canada or Japan

MolMed: submitted the utilisation request concerning the first tranche of the capital increase to be reserved to Société Générale pursuant to the agreement named “SEF - Standby Equity Facility”

Milan (Italy), 26 September 2014 – MolMed S.p.A. (MLM.MI) (“**MolMed**” or the “**Company**”) announces to have submitted to Société Générale (“**SG**”) on 23 September 2014 an utilisation request concerning the subscription of a first tranche (the “**First Tranche**”) of the share capital increase without pre-emptive rights reserved to the same SG (the “**Reserved Capital Increase**”), resolved by the Board of Directors held on 23 September 2014 on the basis of the authorization granted by the Extraordinary Shareholders’ Meeting held on 8 September 2014, pursuant to the agreement named “SEF – Standby Equity Facility” entered into on 31 July 2014 between the Company and SG (the “**Agreement**”). The name “SEF – Standby Equity Facility” is an exclusive trade name of SG.

As already disclosed to the market, pursuant to the Agreement SG has undertaken to subscribe the Reserved Capital Increase upon submission of discretionary subscription requests from the Company (each, a “**Utilisation Request**”) at the terms and conditions specified in the Agreement.

The subscription price of the Shares of the First Tranche, equal to Euro 0.4887 per Share (of which Euro 0.0471 represents capital and the remainder represents share premium), has been determined in the three trading days following the submission of the relevant Utilisation Request by MolMed (i.e., from 24 September 2014 to 26 September 2014 (included)), and is equal to 95% of the Volume Weighted Average Price (“**VWAP**”) of the ordinary shares of the Company as calculated over such period.

Pursuant to the Agreement, with a notice dated as of today, SG has confirmed to subscribe for n. 3,080,670 ordinary shares of the First Tranche, corresponding to the 1.32% of MolMed’s share capital, for an aggregate countervalue equal to Euro 1,505,524.

The proceeds deriving from the Agreement will enable MolMed to increase the flexibility of its financial structure, by diversifying the funding sources aimed at satisfying the Company’s periodic liquidity needs over the term of the Agreement.

Pursuant to the Agreement, SG is not subject to any lock-up on the subscribed Shares and the Company has not executed any agreement with SG for the resale of such shares on the market. No stock lending agreement or guarantee on the Shares is in place between the Company and SG.

The Shares to be issued in relation to the First Tranche, together with any ordinary shares issued in the 12 months preceding the date of the Utilisation Request concerning the First Tranche, do not exceed 10% of the Company’s ordinary shares already admitted to trading on the Italian Stock Exchange on such date and, therefore, the First Tranche of the Reserved Capital Increase is exempt from the obligation to publish a listing prospectus pursuant to Article 57, first paragraph, letter a) of the regulation approved by CONSOB resolution no. 11971/1999.

The settlement of the aforementioned transaction is scheduled for 29 September 2014.

FROM GENES TO THERAPY

MOLMED S.p.A.

Via Olgettina, 58 - 20132 Milan, Italy | Phone +39 02 21277.1 - Fax +39 02 21277.325

info@molmed.com - www.molmed.com

Share capital € 10,874,215.42 fully paid - Office of Milan Company Registry number 1506630 - Tax identification number 11887610159

Not for distribution, directly or indirectly, in the United States of America, Australia, Canada or Japan

This press release is written in compliance with public disclosure obligations established by CONSOB (Italian securities & exchange commission) resolution no. 11971 of 14 May 1999, as subsequently amended.

About MolMed

MolMed S.p.A. is a biotechnology company focused on research, development and clinical validation of novel anticancer therapies. MolMed's pipeline includes two antitumour therapeutics in clinical development: TK, a cell-based therapy enabling bone marrow transplants from partially compatible donors, in absence of post-transplant immune-suppression, in Phase III in high-risk acute leukaemia; NGR-hTNF, a novel vascular targeting agent, in Phase III in malignant pleural mesothelioma and in Phase II in six more indications: colorectal, lung (small-cell and non-small-cell), liver and ovarian cancer, and soft tissue sarcomas. MolMed also offers top-level expertise in cell and gene therapy to third parties to develop, conduct and validate projects from preclinical to Phase III trials, including scale-up and cGMP production of clinical-grade viral vectors, and manufacturing of patient-specific genetically engineered cells. MolMed is headquartered at the San Raffaele Biomedical Science Park in Milan, Italy. The Company's shares are listed on the main market (MTA) of the Milan Stock Exchange. (Ticker Reuters: MLMD.MI)

For further information:

Marina Del Bue

General Manager Business & Administration

Investor Relations Director *ad int.*

MolMed S.p.A.

phone: +39 02 21277.371

fax: +39 02 21277.325

e-mail: investor.relations@molmed.com

Andrea Quaglino

Director of Administration, Finance and Control

MolMed S.p.A.

phone: +39 02 21277.302

fax: +39 02 21277.404

e-mail: afc@molmed.com

Press agent

Federico Ferrari

SEC Relazioni Pubbliche e Istituzionali srl

phone: +39 02 6249991 – mobile +39 347 6456873

e-mail: ferrari@segrp.it

DISCLAIMER

This press release may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, including scientific, business, economic and financial factors, which could cause actual results to differ materially from those anticipated in the forward-looking statements. The company assumes no responsibility to update forward-looking



PRESS RELEASE

Not for distribution, directly or indirectly, in the United States of America, Australia, Canada or Japan

statements or adapt them to future events or developments. This document does not constitute an offer or invitation to subscribe or purchase any securities of MolMed S.p.A.